Home Page

PUNE, India, July 29, 2016 /PRNewswire/ --

ReportnReports.com adds "Gastritis - Pipeline Review, H1 2016" market research report complete with comparative analysis at various stages, gastritis therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastritis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Gastritis with 17 market data tables and 10 figures, spread across 43 pages is available at http://www.reportsnreports.com/reports/601181-gastritis-pipeline-review-h1-2016.html .

The report also reviews key players involved in the therapeutic development for Gastritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Gastritis Pipeline Review, H1 2016 report include BCWorld Pharm Co. Ltd., Daewon Pharm Co. Ltd., Recce Limited and RedHill Biopharma Ltd. Drug Profiles mentioned in this research report are BCWPA-001, DW-3101, netazepide, ondansetron hydrochloride CR, PMKS-005 and RECCE-327.

Order a copy of Gastritis - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=601181 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Gastritis and reviews pipeline therapeutics for Gastritis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Gastritis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Gastritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Gastritis.

Reasons to buy 

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Gastritis
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Gastritis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Another newly published market research report titled on Peritonitis - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Peritonitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritonitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are GlaxoSmithKline Plc, Oncodesign SA and Tobira Therapeutics, Inc. Peritonitis Pipeline market research report of 40 pages is available at http://www.reportsnreports.com/reports/601182-peritonitis-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports